Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current approaches to developing a preventative HIV vaccine.

Tiziana Tonini1, Susan Barnett, John Donnelly

  • 1Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy.

Current Opinion in Investigational Drugs (London, England : 2000)
|March 9, 2005
PubMed
Summary

Developing an effective HIV-1 vaccine requires inducing both antibody and cell-mediated immunity. A major challenge is designing immunogens to elicit potent, broadly reactive antibodies for maximum protection against HIV-1.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation of an antepartum iron deficiency anemia treatment protocol including intravenous iron did not result in lower rates of anemia at birth admission.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same author

Quantitative Outcomes of "Y" Scheduling in an Internal Medicine-Pediatrics Residency Program: First Year Data.

Cureus·2025
Same author

Improving Nursing Home Disaster Readiness Through Implementation Science.

Journal of the American Medical Directors Association·2023
Same author

Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.

The Journal of infection·2022
Same author

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.

Communications biology·2022
Same author

Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.

Biomedicines·2022

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • The field of human immunodeficiency virus type 1 (HIV-1) vaccine development has seen shifts in focus between antibody-only and cell-mediated immunity-only induction strategies over the past two decades.
  • Current consensus suggests that a successful HIV-1 vaccine will necessitate the induction of both humoral (antibody-mediated) and cellular immune responses for optimal protection.

Purpose of the Study:

  • To address the persistent challenge of inducing broadly reactive and potent antibodies with protective functions against HIV-1.
  • To identify key epitopes and design novel immunogens capable of eliciting protective antibody responses.

Main Methods:

  • Review of historical trends and current consensus in HIV-1 vaccine research.
  • Analysis of obstacles in generating protective humoral immunity against HIV-1.

Related Experiment Videos

  • Discussion of epitope-driven immunogen design strategies.

    • Main Results:

    • The field has evolved from favoring antibody-only to cell-mediated immunity-only approaches, with a current consensus favoring combined humoral and cellular immunity.
    • A significant hurdle remains the induction of broadly reactive, potent antibodies crucial for protection.
    • Defining specific epitopes and engineering immunogens are critical for achieving desired antibody responses.

    Conclusions:

    • Inducing both humoral and cellular immunity is essential for an effective HIV-1 vaccine.
    • Overcoming the challenge of generating protective antibodies through epitope and immunogen design is paramount for advancing HIV-1 vaccine development.